Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A quality control product to replace positive blood of patients

A quality control product and positive technology, applied in the field of immunology, can solve problems such as difficult inactivation, difficult standardization, and unstable quality, and achieve the effects of simple production and preparation, reducing detection errors, and avoiding infectivity

Active Publication Date: 2015-11-25
GENCLONN BIOTECH HANGZHOU
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are many disadvantages in using positive blood from patients to prepare positive quality control products: 1) It is difficult to obtain positive blood from patients with high titer and high specificity; ; 3) the cost is relatively high, 4) some pathogen infection cases are scarce, and it is difficult to obtain enough positive blood in a short period of time; At the same time, when collecting and inactivating the patient's positive blood, the operator also has the risk of potential infection
However, the above patents did not disclose the specific composition of the prepared heterologous cross-linked product, which caused the quality of the heterologous cross-linked product to be unstable between different batches, prone to detection errors, and poor substitution

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A quality control product to replace positive blood of patients
  • A quality control product to replace positive blood of patients
  • A quality control product to replace positive blood of patients

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Use SPDP cross-linking agent (purchased from ThermoScientific, product number 21857) to prepare mouse anti-HSV-IIMcAb and healthy non-HSV-II-infected human IgG heterologous cross-linked product as a substitute for HSV-II antibody in positive blood of patients , the process is as follows:

[0044] (1) Dissolve 5 mg mouse anti-HSV-IIMcAb in cross-linking buffer (0.1M potassium phosphate, 0.1M NaCl, pH7.5), stir and add 50 μl SPDP cross-linking agent (3.2 mg / ml, dissolved in absolute ethanol Middle), after reacting at room temperature for 2 hours, put it into a dialysis bag, dialyze with reducing buffer (0.1M sodium acetate, 0.1M NaCl, pH4.5), and change the solution four times;

[0045] (2) Dissolve 5 mg of healthy human IgG uninfected with HSV-II in the cross-linking buffer, stir and add 50 μl SPDP cross-linking agent, react at room temperature for 2 hours, put it into a dialysis bag, and dialyze with the cross-linking buffer, Change the liquid four times;

[0046] (3)...

Embodiment 2

[0052] Example 2 Mouse anti-HSV-IIMcAb and healthy non-infected HSV-II human IgG heterologous cross-linked substance substitution, quality control stability and cryopreservation stability experiments

[0053] The mouse anti-HSV-IIMcAb prepared in Example 1 and the heterologous cross-linked product of healthy human IgG not infected with HSV-II were used as a substitute for the HSV-II antibody in the patient's positive blood to carry out experiments.

[0054] (1) Preparation of quality control products. The heterologous cross-linked products with tetrameric heterologous cross-linked antibodies accounted for 50%, 70%, 90% and 100% of the mass ratio in the prepared heterologous cross-linked products were sequentially prepared as patient Surrogates for HSV-II antibodies in positive blood. When the heterologous cross-linked antibody in tetrameric form accounts for 50%, 70% or 90% of the mass ratio of the prepared heterologous cross-linked product, the remaining 50%, 30% or 10% hete...

Embodiment 3

[0074] Example 3 Mouse anti-HSV-IMcAb and healthy non-infected HSV-1 human IgG heterologous cross-linked substance substitution experiment

[0075] Using SPDP cross-linking agent to prepare mouse anti-HSV-IMcAb and healthy non-infected HSV-I human IgG heterologous cross-linked product as a surrogate for HSV-I antibody in the patient's positive blood, in addition to using mouse anti-HSV- Except that the IMcAb replaced the mouse anti-HSV-IIMcAb, the specific process was the same as in Example 1.

[0076] Experiments were carried out using the mouse anti-HSV-IMcAb prepared in Example 3 and the heterologous cross-linked product of healthy human IgG not infected with HSV-1 as a substitute for the HSV-1 antibody in the patient's positive blood. The heterologous cross-linked products in which the mass ratio of tetrameric heterologous cross-linked antibody in the prepared heterologous cross-linked product is 50%, 70%, 90% and 100% are sequentially prepared. When the heterologous cros...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention provides a heterologous cross-linking object containing heterologous cross-linking antibody in a tetramer form, the heterologous cross-linking object is obtained from cross-linking reactions between two heterologous antibodies, the mass ratio of the heterologous cross-linking antibody in a tetramer form in the heterologous cross-linking object is preferably not less than 50%, the heterologous cross-linking object can be taken as a substituent of a pathogen antibody in the patients' positive blood, and can be applied to a immunity detection kit as a quality control object to substitute the patients' positive blood after being diluted by a diluting liquid. The heterologous cross-linking object has the advantages of simple production and preparation, low cost, and very good stability and safety. Furthermore, qualities of different batches of quality control objects are stable, so detection errors can be effectively reduced.

Description

technical field [0001] The present invention relates to a quality control product that can replace the patient's positive blood. The quality control product includes a diluent and a heterologous cross-linked antibody in the form of a tetramer obtained from two heterologous antibodies through a cross-linking reaction. The heterologous cross-linked product belongs to the technical field of immunology. Background technique [0002] Pathogens such as viruses, bacteria, fungi and parasites pose an increasing threat to humans today. Immunoassay methods based on specific and highly sensitive reactions between antigens and antibodies, such as colloidal gold immunochromatography, latex immunochromatography, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), time-resolved Fluorescence immunoassay (TRFIA) or chemiluminescence immunoassay (CLIA) have been widely used in clinical immunoassays. These immunoassay methods are generally used to qualitatively or quantitative...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/531
CPCY02A50/30
Inventor 潘剑用周海涛闵丹
Owner GENCLONN BIOTECH HANGZHOU
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com